Latest Commercialisation News

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Southern Cross Gold Consolidated has announced a major metallurgical advancement at its Sunday Creek project, delivering a high-grade, low-arsenic antimony-gold concentrate alongside excellent gold recovery. This development enhances the project's economic potential amid shifting global supply dynamics for critical metals.

FBR Limited has locked in a A$20 million share subscription facility with GEM Global Yield LLC, providing flexible capital to advance its innovative robotics platforms and commercialisation efforts.

ABx Group has sent a 100 kg bulk sample from its Deep Leads rare earths project to ANSTO for production of a high-purity mixed rare earth carbonate, confirming exceptional grades and extraction potential. The milestone underscores ABx’s progress toward low-cost, environmentally friendly rare earth supply.

G50 Corp has identified sericite as the primary host mineral for gallium at its Golconda Project, marking a pivotal step toward developing a domestic US supply of this critical metal. Recent drilling confirms consistent high-grade gallium alongside precious metals, advancing commercial extraction prospects.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

Firebird Metals has received a significant Expression of Interest from Taza Metal Technologies to purchase up to five of its energy-efficient kilns, potentially generating over US$10 million in revenue. This marks a key step in Firebird’s international commercial expansion and highlights its leadership in sustainable manganese processing technology.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.